Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 3Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Other neoplasm 1

Conditions

Neoplasms 1331Breast Neoplasms 688Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 437Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 366Lymphoma, Non-Hodgkin 356Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 267Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 254Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Hodgkin Disease 193Carcinoma, Renal Cell 193Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Glioma 172Burkitt Lymphoma 172

Interventions

pirfenidone 1Sorafenib 1Pharmacokinetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Neurofibroma, Plexiform × Clear all
NCT00727233 2019-12-12

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
9 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT00053937 2015-04-30

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

National Cancer Institute (NCI)

Phase 1 Completed
CNSOther neoplasm

Neurofibromatosis 1, Precancerous Conditions, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡